Topics

FDA Approves Celgene’s Reblozyl for Treatment of Anemia in Adults with Beta Thalassemia who Require Regular Red Blood Cell Transfusions

15:35 EST 8 Nov 2019 | Speciality Pharma Journal

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.1 REBLOZYL is not indicated for use as a substitute for …

Original Article: FDA Approves Celgene’s Reblozyl for Treatment of Anemia in Adults with Beta Thalassemia who Require Regular Red Blood Cell Transfusions

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Celgene’s Reblozyl for Treatment of Anemia in Adults with Beta Thalassemia who Require Regular Red Blood Cell Transfusions"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...